Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

Inclusion Criteria: * Patients must have a histologically and cytological confirmed acute myeloid leukemia, high risk AML defined as: * Age \> 60, or * Presence of complex cytogenetic abnormalities (with \> 3 cytogenetic abnormalities), del (7q, -5, -7), t(9,22), 11q(23) or high risk mutations by FISH eg MLL, FLT-3 + * Secondary AML, or * A white blood cell count of \> 50 x10\^9/L * Patients must be medically ineligible for allogeneic stem cell transplant (alloSCTx) or not have a known fully HLA matched sibling for planned sibling transplant. * Patients must have measurable or evaluable disease * Diagnosis of AML according to World Health Organization (WHO) diagnostic criteria (at least 20% blasts in the peripheral blood or bone marrow), with French-American-British Cooperative group (FAB) classification other than M3 (acute promyelocytic leukemia), documented by bone marrow aspiration and biopsy performed within 14 days prior to administration of 1st dose of remission induction chemotherapy; if a bone marrow aspirate and biopsy were obtained within 28 days prior to the first dose of remission induction therapy then these tests may be submitted for review at University of Southern California (USC) and a repeat screening bone marrow does not need to be conducted; * Cohort A: newly diagnosed AML, no prior cytotoxic chemotherapy * Cohort B: newly diagnosed AML, failed to achieve Complete remission (CR) with single standard Induction chemo. * Patient has at least o…